ArticleJournal of virology2011
Inhibition of dengue virus infections in cell cultures and in AG129 mice by a small interfering RNA targeting a highly conserved sequence.
Article in Journal of virology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 57 citations in OpenAlex.
- Therapeutic Approaches of Viral Gene Silencing by Small Interfering RNA: Strategies to Prevent the Emergence of Antiviral Resistant Escape Mutants.Pharmaceuticals (Basel, Switzerland) · 2025Review
- In Vitro Inhibitory Analysis of Rationally Designed siRNAs against MERS-CoV Replication in Huh7 Cells.Molecules (Basel, Switzerland) · 2021Article
- Targeting Chikungunya Virus Replication by Benzoannulene Inhibitors.Journal of medicinal chemistry · 2021Article
- Oligonucleotide-Based Approaches to Inhibit Dengue Virus Replication.Molecules (Basel, Switzerland) · 2021Review
- Antiviral Activity of Compound L3 against Dengue and Zika Viruses In Vitro and In Vivo.International journal of molecular sciences · 2020Article
- The E3 Ubiquitin Ligase SIAH1 Targets MyD88 for Proteasomal Degradation During Dengue Virus Infection.Frontiers in microbiology · 2020Article
- siRNA Design to Silence the 3'UTR Region of Zika Virus.BioMed research international · 2020Article
- Small Molecules Targeting the Flavivirus E Protein with Broad-Spectrum Activity and Antiviral Efficacy in Vivo.ACS infectious diseases · 2019Article
- A review on current status of antiviral siRNA.Reviews in medical virology · 2018Review
- Deletion of PRKAA triggers mitochondrial fission by inhibiting the autophagy-dependent degradation of DNM1L.Autophagy · 2017Article
- A Molecular Approach Designed to Limit the Replication of Mature DENV2 in Host Cells.Viral immunology · 2015Article
- Role of human heterogeneous nuclear ribonucleoprotein C1/C2 in dengue virus replication.Virology journal · 2015Article
- Endothelial cells in dengue hemorrhagic fever.Antiviral research · 2014Review
- Delivery of antiviral small interfering RNA with gold nanoparticles inhibits dengue virus infection in vitro.The Journal of general virology · 2014Article
- VIRsiRNApred: a web server for predicting inhibition efficacy of siRNAs targeting human viruses.Journal of translational medicine · 2013Article
- Inhibition of Dengue virus 2 replication by artificial micrornas targeting the conserved regions.Nucleic acid therapeutics · 2013Article
- RNAi: antiviral therapy against dengue virus.Asian Pacific journal of tropical biomedicine · 2013Review
- Arthropod-borne flaviviruses and RNA interference: seeking new approaches for antiviral therapy.Advances in virus research · 2013Review
- Article
- SiRNA inhibits replication of Langat virus, a member of the tick-borne encephalitis virus complex in organotypic rat brain slices.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
Abstract
The dengue viruses (DENVs) exist as numerous genetic strains that are grouped into four antigenically distinct serotypes. DENV strains from each serotype can cause severe disease and threaten public health in tropical and subtropical regions worldwide. No licensed antiviral agent to treat DENV infections is currently available, and there is an acute need for the development of novel therapeutics. We found that a synthetic small interfering RNA (siRNA) (DC-3) targeting the highly conserved 5' cyclization sequence (5'CS) region of the DENV genome reduced, by more than 100-fold, the titers of representative strains from each DENV serotype in vitro. To determine if DC-3 siRNA could inhibit DENV in vivo, an "in vivo-ready" version of DC-3 was synthesized and tested against DENV-2 by using a mouse model of antibody-dependent enhancement of infection (ADE)-induced disease. Compared with the rapid weight loss and 5-day average survival time of the control groups, mice receiving the DC-3 siRNA had an average survival time of 15 days and showed little weight loss for approximately 12 days. DC-3-treated mice also contained significantly less virus than control groups in several tissues at various time points postinfection. These results suggest that exogenously introduced siRNA combined with the endogenous RNA interference processing machinery has the capacity to prevent severe dengue disease. Overall, the data indicate that DC-3 siRNA represents a useful research reagent and has potential as a novel approach to therapeutic intervention against the genetically diverse dengue viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.